Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Emerging anti-inflammatory drugs for atherosclerosis.

Authors
  • Berman, Jeremy P
  • Farkouh, Michael E
  • Rosenson, Robert S
Type
Published Article
Journal
Expert opinion on emerging drugs
Publication Date
Jun 01, 2013
Volume
18
Issue
2
Pages
193–205
Identifiers
DOI: 10.1517/14728214.2013.801453
PMID: 23675745
Source
Medline
License
Unknown

Abstract

Currently, only three anti-inflammatory drugs (methotrexate, darapladib and canakinumab) are being investigated in Phase III clinical trials of atherosclerosis. The development of cardiovascular drugs requires long, expensive Phase III trials to demonstrate incremental improvement in cardiovascular events. Imaging end points and soluble biomarkers accelerate Phase II development, but further validation is needed before these can be used as surrogate end points in the large trials leading to drug approval. Improved access to currently available therapies like statins would decrease the burden of cardiovascular disease worldwide.

Report this publication

Statistics

Seen <100 times